GU Cancers Symposium 2014 - Biomarker analysis from a phase III trial (GOLD) of dovitinib vs sorafenibin patients with metastatic renal cell carcinoma after one prior VEGF pathway-targeted therapy and one prior mTOR inhibitor therapy - Poster

SAN FRANCISCO, CA USA (UroToday.com) - Presented by Bernard J. Escudier, Camillo Porta, Matthew Squires, Cezary Szczylik, Christian K. Kollmannsberger, Bohuslav Melichar, Sun Young Rha, Emilio Esteban, Georg A. Bjarnason, Nicholas J. Vogelzang, Cora N. Sternberg, Michael Shi, Mathab Marker, and Robert John Motzer at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

gucancer 2014 Poster Escudier thumb

Institut Gustave Roussy, Villejuif, France; IRCCS San Matteo University Hospital Foundation, Pavia, Italy; Novartis Pharma AG, Basel, Switzerland; Military Institute of Health Services in Warsaw, Warsaw, Poland; BCCA Vancouver Cancer Centre, Vancouver, BC, Canada; Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic; Yonsei University College of Medicine, Seoul, South Korea; Hospital Universitario Central de Asturias, Oviedo, Spain; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Comprehensive Cancer Centers of Nevada, Las Vegas, NV; San Camillo and Forlanini Hospital, Rome, Italy; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Memorial Sloan-Kettering Cancer Center, New York, NY

 

 

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe